Gland Pharma Share Price in Focus After Hitting 52-Week High as Q2 Profit Jumps 58%

Gland Pharma shares rose around 7% on 9 November, reaching an intraday high of ₹3,374 on the NSE. The stock moved higher despite selling pressure across the broader Indian market. 

The latest rise follows the company's Q2 FY27 results, which showed growth in revenue and profit alongside an improvement in operating margins. Gland Pharma shares have gained 93.87% year-to-date. 

Gland Pharma Reports 58% Profit Growth 

The drugmaker reported a net profit of ₹291 crore for the second quarter of FY27, compared with ₹184 crore in the same period last year, marking a 58.2% increase. 

Revenue grew 23.3% year-on-year to ₹1,834 crore from ₹1,487 crore. EBITDA also recorded strong growth, rising 54.1% to ₹484 crore against ₹314 crore in the corresponding quarter. 

The EBITDA margin improved to 26.4% from 21.1%. Adjusted EBITDA increased 50% year-on-year, with the adjusted margin at 27%. The company's PAT margin expanded by approximately 350 basis points during the quarter. 

R&D Expenditure Increases 

Gland Pharma spent ₹107.7 crore on research and development in Q2 FY27, compared with ₹81.7 crore a year earlier. This represented 6% of consolidated revenue. 

The expenditure was primarily directed towards developing complex products and expanding the company's filing pipeline. 

Stock Records Strong Year-to-Date Gains 

The stock has gained 8.43% over the past week and 8.60% in the last month. Its year-to-date return stands at 93.87%, while it has advanced 78.48% over the past year. 

Read More: Larsen & Toubro Share Price in Focus; Secures Noida Metro Aqua Line Extension Project Order! 

Conclusion 

Gland Pharma's Q2 FY27 performance included higher revenue, stronger profitability and increased R&D spending. The stock also reached a new 52-week high during Monday's trading session. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.